Evidence map›Paper›PMID 23592987›Full record

ArticlePLoS pathogens2013

Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.

Nicolas A Gillet, Lucy Cook, Daniel J Laydon, Carol Hlela, Kristien Verdonck, Carolina Alvarez, Eduardo Gotuzzo, Daniel Clark, Lourdes Farré, Achiléa Bittencourt and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Human T-Cell Lymphotropic Virus Type 1 andFrontiers in medicine · 2022
    Pooled it
  2. Review
  3. Review
  4. Upregulation of Neuropilin-1 Inhibits HTLV-1 Infection.Pathogens (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Evaluation of Strongyloides stercoralis infection in patients with HTLV-1.Biomedica : revista del Instituto Nacional de Salud · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Human T-cell Leukemia Virus Type 1 andPathogens (Basel, Switzerland) · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Nicolas A GilletSection of Immunology, Wright-Fleming Institute, Imperial College London, London, United Kingdom. n.gillet@ulg.ac.be
Lucy Cook
Daniel J Laydon
Carol Hlela
Kristien Verdonck
Carolina Alvarez
Eduardo Gotuzzo
Daniel Clark
Lourdes Farré
Achiléa Bittencourt
Becca Asquith
Graham P Taylor
Charles R M Bangham
Imperial College London · GBHospital Nacional Cayetano Heredia · PEFundação Oswaldo Cruz · BRUniversidade Federal da Bahia · BRUniversidad Peruana Cayetano Heredia · PE

Funding

Medical Research Council G0601072Medical Research Council MR/J007439/1Medical Research Council MR/K019090/1Wellcome Trust 100291
6 · The paper itself

Abstract

Human T-lymphotropic Virus-1 (HTLV-1) is a retrovirus that persists lifelong by driving clonal proliferation of infected T-cells. HTLV-1 causes a neuroinflammatory disease and adult T-cell leukemia/lymphoma. Strongyloidiasis, a gastrointestinal infection by the helminth Strongyloides stercoralis, and Infective Dermatitis associated with HTLV-1 (IDH), appear to be risk factors for the development of HTLV-1 related diseases. We used high-throughput sequencing to map and quantify the insertion sites of the provirus in order to monitor the clonality of the HTLV-1-infected T-cell population (i.e. the number of distinct clones and abundance of each clone). A newly developed biodiversity estimator called "DivE" was used to estimate the total number of clones in the blood. We found that the major determinant of proviral load in all subjects without leukemia/lymphoma was the total number of HTLV-1-infected clones. Nevertheless, the significantly higher proviral load in patients with strongyloidiasis or IDH was due to an increase in the mean clone abundance, not to an increase in the number of infected clones. These patients appear to be less capable of restricting clone abundance than those with HTLV-1 alone. In patients co-infected with Strongyloides there was an increased degree of oligoclonal expansion and a higher rate of turnover (i.e. appearance and disappearance) of HTLV-1-infected clones. In Strongyloides co-infected patients and those with IDH, proliferation of the most abundant HTLV-1⁺ T-cell clones is independent of the genomic environment of the provirus, in sharp contrast to patients with HTLV-1 infection alone. This implies that new selection forces are driving oligoclonal proliferation in Strongyloides co-infection and IDH. We conclude that strongyloidiasis and IDH increase the risk of development of HTLV-1-associated diseases by increasing the rate of infection of new clones and the abundance of existing HTLV-1⁺ clones.

Indexed as

Strongyloides stercoralisViral LoadAdultAnimalsCoinfectionDermatitisHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellMiddle AgedProvirusesRisk FactorsStrongyloidiasisT-Lymphocytes

Identifiers

PMID23592987
PMCPMC3617147
OpenAlexW2051936933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.